Boston Scientific (NYSE:BSX) Releases Earnings Results, Beats Expectations By $0.03 EPS

Boston Scientific (NYSE:BSX) released its quarterly earnings results on Wednesday. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03, FiscalAI reports. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.36 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific updated its Q3 2026 guidance to 0.800-0.820 EPS and its FY 2026 guidance to 3.280-3.320 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Second-quarter results exceeded guidance, with organic revenue growth of 7% and adjusted EPS of $0.86, up 15% year over year and above the $0.82–$0.84 forecast range.
• Boston Scientific reduced its 2026 outlook to 5%–6% organic revenue growth and adjusted EPS of $3.28–$3.32, citing sharper-than-expected pressure in U.S. electrophysiology and a slowdown in WATCHMAN adoption.
• WATCHMAN growth is expected to decline mid- to high-single digits globally in the second half, while EP growth is expected to be flat; management also anticipates limited EPS growth and margin pressure in 2027.
• A company-wide restructuring program is expected to generate approximately $500 million in annualized savings by the end of 2029, with more than half realized by the end of 2027 and reinvestment directed toward priority growth areas.
• Management highlighted strong momentum in interventional cardiology, neuromodulation, interventional oncology, and vascular therapies, alongside longer-term catalysts including Penumbra, coronary IVL, FARAWAVE Ultra, ICE imaging, and potential MiRus TAVR assets.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock traded up $0.13 during trading hours on Wednesday, hitting $46.19. The company’s stock had a trading volume of 30,334,756 shares, compared to its average volume of 18,167,727. The stock has a market cap of $68.65 billion, a price-to-earnings ratio of 19.34, a P/E/G ratio of 0.87 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The firm has a fifty day moving average of $46.78 and a 200-day moving average of $63.10.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Sunbelt Securities Inc. grew its position in Boston Scientific by 33.0% in the 4th quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 350 shares in the last quarter. Compound Planning Inc. lifted its position in shares of Boston Scientific by 14.7% during the fourth quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider’s stock worth $1,471,000 after purchasing an additional 1,978 shares in the last quarter. Axxcess Wealth Management LLC boosted its stake in shares of Boston Scientific by 130.9% in the fourth quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider’s stock valued at $2,703,000 after purchasing an additional 16,068 shares during the period. Corient Private Wealth LLC grew its holdings in shares of Boston Scientific by 11.1% in the fourth quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider’s stock valued at $22,238,000 after purchasing an additional 24,194 shares in the last quarter. Finally, Strive Financial Group LLC purchased a new stake in Boston Scientific during the 4th quarter worth approximately $1,499,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on BSX. Evercore set a $65.00 target price on Boston Scientific in a report on Monday, July 6th. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Citigroup dropped their target price on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 28th. Finally, Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $78.40.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded expectations with adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.442 billion versus $5.36 billion. Revenue increased 7.5% year over year, while adjusted EPS rose from $0.75 in the prior-year quarter. Boston Scientific Announces Second-Quarter Results
• Positive Sentiment: Growth was broad-based: Cardiovascular sales increased 8.3%, with particularly strong reported growth in APAC and LACA. U.S. sales rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4%, while margin expansion also supported the quarterly performance. Boston Scientific Q2 Earnings and Revenue Beat
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase, buying back approximately 40 million shares. It also invested $1.5 billion for a roughly 34% stake in MiRus and an option to acquire its TAVR business, potentially strengthening Boston Scientific’s structural-heart portfolio. Boston Scientific Q2 Revenue Report
• Neutral Sentiment: Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, adding a new commercial opportunity, although the immediate financial impact is unclear.
• Negative Sentiment: Management reduced 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41 and forecast revenue of $21.2-$21.4 billion, below the approximately $21.6 billion consensus. Third-quarter guidance of $0.80-$0.82 EPS and $5.2-$5.3 billion revenue also trails analyst expectations. Boston Scientific Lowers Annual Profit Forecast
• Negative Sentiment: The outlook reduction reflects slower demand for the Watchman heart device, product-growth moderation and increased competition. A global restructuring plan is expected to involve headcount reductions and $700 million-$800 million of costs through 2029, although management targets approximately $500 million in annual savings. Boston Scientific Cuts Outlook Ahead of Restructuring
• Negative Sentiment: UBS lowered its price target to $74 from $95 while retaining a Buy rating, signaling reduced near-term expectations despite confidence in Boston Scientific’s longer-term prospects. UBS Adjusts Boston Scientific Price Target

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.